|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Akela Pharma Inc., of Montreal, completed enrolling patients in its Fentanyl Taifun Phase IIb trial. The product is a fast-acting fentanyl formulation delivered using the company's Taifun dry-powder inhaler platform. The multinational trial is being run in cancer patients on maintenance opioid therapy who have severe persistent pain. The first part of the trial is an open-label study to evaluate dosing. The second part includes 28 responders from the open-label arm randomized to receive the titrated doses or placebo. Safety and efficacy data from the double-blind, placebo-controlled extension arm are expected to be available by early September.
o EpiCept Corp., ...